Skip to main content
SpringerLink
Log in

Survival and Growth of Prostate Cancer Cells in the Bone: Role of the Alpha-Receptor for Platelet-Derived Growth Factor in Supporting Early Metastatic Foci

  • Chapter
  • First Online:
Signaling Pathways and Molecular Mediators in Metastasis

  • 1252 Accesses

Abstract

Skeletal dissemination is by far the most feared complication of prostate cancer and the main cause of patients’ demise. Today, 85% of patients are diagnosed with prostate cancer in the absence of clinically evident secondary tumors. However, a significant number of these patients will eventually develop the advanced form of the disease and present with skeletal metastases. A definitive, curative treatment for bone metastatic disease is still an unmet clinical need and the current standard of care relies on merely palliative measures.

There is vast consensus on the fact that cancer cells that spread to the skeleton need to find favorable local conditions to survive and grow. Indeed, those cells that fail to receive appropriate support will either remain dormant or undergo cell death, thereby exerting a negligible clinical impact on patients’ quality of life and overall survival. Significant efforts have been made to identify the cellular events as well as signaling molecules and mechanisms implicated in the growth of cancer cells in the bone marrow. Pre-clinical and clinical studies have investigated the role exerted by the receptors for Platelet-Derived Growth Factor (PDGFRs) in promoting skeletal metastases. Interestingly, the alpha isoform of PDGFR (PDGFRα) appears to be directly implicated in the initial colonization of the skeleton, a step of metastatic progression that might have been significantly overlooked.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695

    Article  PubMed  CAS  Google Scholar 

  2. Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222:1–15

    Article  PubMed  CAS  Google Scholar 

  3. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564

    Article  PubMed  CAS  Google Scholar 

  4. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134.

    Article  PubMed  CAS  Google Scholar 

  5. Al-Mehdi AB, Tozawa K, Fisher AB et al (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6:100–102

    Article  PubMed  CAS  Google Scholar 

  6. Alix-Panabières C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res: an official journal of the American Association for Cancer Research 14:5013–5021

    Article  PubMed  Google Scholar 

  7. Glinskii O, Huxley V, Glinsky G et al (2005) Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7:522–527

    Article  PubMed  CAS  Google Scholar 

  8. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284

    Article  PubMed  CAS  Google Scholar 

  9. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  PubMed  CAS  Google Scholar 

  10. Shibue T, Weinberg RA (2011) Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 21:99–106

    Article  PubMed  CAS  Google Scholar 

  11. Weinberg RA (2008) The many faces of tumor dormancy. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 116:548–551

    PubMed  Google Scholar 

  12. Lin H, Balic M, Zheng S et al (2011) Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol 77:1–11

    Article  PubMed  Google Scholar 

  13. Cawthorn TR, Amir E, Broom R et al (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 26:935–943

    Article  PubMed  CAS  Google Scholar 

  14. Roodman GD (2007) Bone-breaking cancer treatment. Nat Med 13:25–26

    Article  PubMed  CAS  Google Scholar 

  15. Buijs JT, van der Pluijm G (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett 273:177–193

    Article  PubMed  CAS  Google Scholar 

  16. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664

    Article  PubMed  CAS  Google Scholar 

  17. Kingsley LA, Fournier PG, Chirgwin JM et al (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609–2617

    Article  PubMed  CAS  Google Scholar 

  18. Cheville JC, Tindall D, Boelter C et al (2002) Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95:1028–1036

    Article  PubMed  Google Scholar 

  19. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718–729

    Article  PubMed  CAS  Google Scholar 

  20. Lee RJ, Saylor PJ, Smith MR (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:88–95

    Article  PubMed  CAS  Google Scholar 

  21. Jones DH, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696

    Article  PubMed  CAS  Google Scholar 

  22. Saad F, Schulman CC (2004) Role of bisphosphonates in prostate cancer. Eur Urol 45:26–34

    Article  PubMed  CAS  Google Scholar 

  23. Bouganim N, Clemons MJ (2011) Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 7:381–383

    Article  PubMed  CAS  Google Scholar 

  24. Nyambo R, Cross N, Lippitt J et al (2004) Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19:1712–1721

    Article  PubMed  CAS  Google Scholar 

  25. Corey E, Brown LG, Kiefer JA et al (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65:1710–1718

    Article  PubMed  CAS  Google Scholar 

  26. Canon JR, Roudier M, Bryant R et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119–129

    Article  PubMed  CAS  Google Scholar 

  27. Lee Y-P, Schwarz EM, Davies M et al (2002) Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62:5564–5570

    PubMed  CAS  Google Scholar 

  28. Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 9:295–306

    PubMed  CAS  Google Scholar 

  29. Thudi NK, Martin CK, Nadella MVP et al (2008) Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate 68:1116–1125

    Article  PubMed  CAS  Google Scholar 

  30. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174

    Article  PubMed  CAS  Google Scholar 

  31. Bagi CM (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57:995–1010

    Article  PubMed  CAS  Google Scholar 

  32. Coleman RE, Guise T, Lipton A et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14:6387–6395

    Article  PubMed  Google Scholar 

  33. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    Article  PubMed  CAS  Google Scholar 

  34. Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139

    Article  PubMed  CAS  Google Scholar 

  35. van der Pluijm G, Que I, Sijmons B et al (2005) Interference with the microenviron­mental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65:7682–7690

    PubMed  Google Scholar 

  36. Clarke NW, Hart CA, Brown MD (2009) Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 11:57–67

    Article  PubMed  CAS  Google Scholar 

  37. Russell M, Jamieson W, Dolloff N et al (2009) The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28:412–421

    Article  PubMed  CAS  Google Scholar 

  38. Ohmori K, Matsui H, Yasuda T et al (1997) Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol 27:263–267

    Article  PubMed  CAS  Google Scholar 

  39. Fidler I (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458

    Article  PubMed  CAS  Google Scholar 

  40. Mundy GR (2000) Structure and physiology of the normal skeleton. In: Robert D, Rubens GRM (ed) Cancer and the skeleton, 3rd edn. London, UK: Informa Healthcare, pp 1–19

    Google Scholar 

  41. Zhang S, Wang J, Bilen M et al (2009) Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis 26(8):993–1004

    Article  PubMed  CAS  Google Scholar 

  42. Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298–1312

    Article  PubMed  CAS  Google Scholar 

  43. Bussard KM, Venzon DJ, Mastro AM (2010) Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J Cell Biochem 111(5):1138–1148

    Article  PubMed  CAS  Google Scholar 

  44. Bidard F-C, Pierga J-Y, Vincent-Salomon A et al (2008) A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev 27:5–10

    Article  PubMed  CAS  Google Scholar 

  45. Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093

    Article  PubMed  CAS  Google Scholar 

  46. Kaplan RN, Psaila B, Lyden D (2007) Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 13:72–81

    Article  PubMed  CAS  Google Scholar 

  47. Fidler I, Poste G (2008) The “seed and soil” hypothesis revisited. Lancet Oncol 9:808

    Article  PubMed  Google Scholar 

  48. Chott A, Sun Z, Morganstern D et al (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271–1279

    Article  PubMed  CAS  Google Scholar 

  49. Fudge K, Wang CY, Stearns ME (1994) Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta-receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 7:549–554

    PubMed  CAS  Google Scholar 

  50. Dolloff N, Shulby S, Nelson A et al (2005) Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene 24:6848–6854

    Article  PubMed  CAS  Google Scholar 

  51. Kamb A, Wee S, Lengauer C (2007) Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6:115–120

    Article  PubMed  CAS  Google Scholar 

  52. Yang D (2000) Platelet-derived growth factor (PDGF)-AA: a self-imposed cytokine in the proliferation of human fetal osteoblasts. Cytokine 12:1271–1274

    Article  PubMed  CAS  Google Scholar 

  53. Dolloff N, Russell MR, Loizos N et al (2007) Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res 67:555–562

    Article  PubMed  CAS  Google Scholar 

  54. Russell MR, Liu Q, Lei H et al (2010) The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-­independent mechanisms. Cancer Res 70:4195–4203

    Article  PubMed  CAS  Google Scholar 

  55. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316

    PubMed  CAS  Google Scholar 

  56. Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204

    Article  PubMed  CAS  Google Scholar 

  57. Kazlauskas A, Cooper JA (1989) Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 58:1121–1133

    Article  PubMed  CAS  Google Scholar 

  58. Bishayee S, Majumdar S, Khire J et al (1989) Ligand-induced dimerization of the platelet-derived growth factor receptor. Monomer-dimer interconversion occurs independent of receptor phosphorylation. J Biol Chem 264:11699–11705

    PubMed  CAS  Google Scholar 

  59. Baxter RM, Secrist JP, Vaillancourt RR et al (1998) Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J Biol Chem 273:17050–17055

    Article  PubMed  CAS  Google Scholar 

  60. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927

    Article  PubMed  CAS  Google Scholar 

  61. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

    Article  PubMed  CAS  Google Scholar 

  62. Luo J, Manning B, Cantley L (2003) Targeting the PI3K-Akt pathway in human cancer Rationale and promise. Cancer Cell 4:257–262

    Article  PubMed  CAS  Google Scholar 

  63. Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603

    Article  PubMed  CAS  Google Scholar 

  64. Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435–2444

    PubMed  CAS  Google Scholar 

  65. Chang F, Steelman LS, Lee JT et al (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263–1293

    Article  PubMed  CAS  Google Scholar 

  66. Berridge M, Bootman M, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4:517–529

    Article  PubMed  CAS  Google Scholar 

  67. Gelderloos JA, Rosenkranz S, Bazenet C et al (1998) A role for Src in signal relay by the platelet-derived growth factor alpha receptor. J Biol Chem 273:5908–5915

    Article  PubMed  CAS  Google Scholar 

  68. DeMali KA, Godwin SL, Soltoff SP et al (1999) Multiple roles for Src in a PDGF-stimulated cell. Exp Cell Res 253:271–279

    Article  PubMed  CAS  Google Scholar 

  69. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480

    Article  PubMed  CAS  Google Scholar 

  70. Im E, Kazlauskas A (2007) Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 282:29122–29129

    Article  PubMed  CAS  Google Scholar 

  71. Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15:215–228

    Article  PubMed  CAS  Google Scholar 

  72. Tallquist M, Kazlauskas A (2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205–213

    Article  PubMed  CAS  Google Scholar 

  73. Hoch RV (2003) Roles of PDGF in animal development. Dev Suppl 130:4769–4784

    CAS  Google Scholar 

  74. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312

    Article  PubMed  CAS  Google Scholar 

  75. Yarden Y, Escobedo JA, Kuang WJ et al (1986) Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323:226–232

    Article  PubMed  CAS  Google Scholar 

  76. Von Mehren M (2004) Targeted therapy with imatinib: hits and misses? J Clin Oncol 23:8–10

    Article  Google Scholar 

  77. George DJ (2002) Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 60:115–121; ­discussion 122

    Article  PubMed  Google Scholar 

  78. Uehara H, Kim S, Karashima T et al (2003) Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458

    Article  PubMed  CAS  Google Scholar 

  79. Kim SJ, Uehara H, Yazici S et al (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98:783–793

    Article  PubMed  CAS  Google Scholar 

  80. Catena R, Luis-Ravelo D, Antón I et al (2011) PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res 71:164–174

    Article  PubMed  CAS  Google Scholar 

  81. Rao K, Goodin S, Levitt M et al (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115–122

    Article  PubMed  CAS  Google Scholar 

  82. Lin A, Rini B, Weinberg V et al (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98:763–769

    Article  PubMed  CAS  Google Scholar 

  83. Shah GD, Loizos N, Youssoufian H et al (2010) Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α. Cancer 116:1018–1026

    Article  PubMed  CAS  Google Scholar 

  84. Loizos N, Xu Y, Huber J et al (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4:369–379

    PubMed  CAS  Google Scholar 

  85. Russell MR, Liu Q, Fatatis A (2010) Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 16:5002–5010

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Physiology, Drexel University, College of Medicine, 245 N. 15th Street, MS 488, Philadelphia, PA, 19102, USA

    Qingxin Liu, Yun Zhang, Danielle Jernigan & Alessandro Fatatis

  2. Department of Pathology and Laboratory Medicine, Drexel University, College of Medicine, Philadelphia, PA, USA

    Alessandro Fatatis

Authors
  1. Qingxin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Danielle Jernigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Fatatis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Fatatis .

Editor information

Editors and Affiliations

  1. Drexel University College of Medicine, N. 15th Street 245, Philadelphia, 19102, Pennsylvania, USA

    Alessandro Fatatis

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Liu, Q., Zhang, Y., Jernigan, D., Fatatis, A. (2011). Survival and Growth of Prostate Cancer Cells in the Bone: Role of the Alpha-Receptor for Platelet-Derived Growth Factor in Supporting Early Metastatic Foci. In: Fatatis, A. (eds) Signaling Pathways and Molecular Mediators in Metastasis. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2558-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation